Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.43 |
| ▸ | VDR | P11473 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125845 | 0.91 | L3MBTL1 (0.54) | L3MBTL1NR1H4VDRHSD17B10GAA | |
| SCHEMBL14382790 | 0.83 | L3MBTL1 (0.63) | L3MBTL1NR1H4VDRHSD17B10GAA | |
| SCHEMBL4124520 | 0.83 | L3MBTL1 (0.52) | L3MBTL1NR1H4VDRHSD17B10GAA | |
| SCHEMBL4125294 | 0.81 | L3MBTL1 (0.58) | L3MBTL1NR1H4VDRHSD17B10GAA | |
| SCHEMBL4134033 | 0.81 | L3MBTL1 (0.52) | L3MBTL1NR1H4VDRHSD17B10GAA | |
| SCHEMBL13904523 | 0.81 | L3MBTL1 (0.47) | L3MBTL1NR1H4VDRHSD17B10RPS6KB1 | |
| SCHEMBL4130835 | 0.80 | L3MBTL1 (0.58) | L3MBTL1NR1H4VDRHSD17B10GAA | |
| SCHEMBL4122761 | 0.80 | L3MBTL1 (0.57) | L3MBTL1NR1H4VDRHSD17B10GAA | |
| SCHEMBL4125933 | 0.80 | L3MBTL1 (0.51) | L3MBTL1NR1H4VDRHSD17B10GAA | |
| SCHEMBL4116517 | 0.80 | L3MBTL1 (0.55) | L3MBTL1NR1H4VDRHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | claimed |
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| EP-1545486-A1 | USE OF BUPROPION FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RESTLESS LEGS SYNDROME | Pharmacia & Upjohn Company LLC (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004017951-A1 | USE OF BUPROPION FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RESTLESS LEGS SYNDROME | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | HAVCR2, MAVS, ZC3HAV1 | L3MBTL1 1221/4885NR1H4 774/4885VDR 2346/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | L3MBTL1 1221/4885NR1H4 774/4885VDR 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.